Home›Stock Screener›EIKO Lifesciences›Financial Statements

EIKO Lifesciences Complete Financial Statements

7 Years of Data
2026 - 2017

In FY2026, EIKO Lifesciences (EIKO) reported revenue ₹19 Cr, net profit ₹2 Cr and EPS ₹0.93, with a net profit margin of 10.5% and ROE of 2.9%. Full financial statements from FY2017 to FY2026 (7 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review EIKO Lifesciences P/E valuation to evaluate earnings-based valuation against sector peers.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 10.53% 2026 data
EBITDA Margin 10.53% 2026 data
Operating Margin 12.00% 2026 data
Return on Assets 2.25% 2026 data
Return on Equity 2.90% 2026 data

Balance Sheet Ratios

Current Ratio 11.75 2026 data
Equity Ratio 77.53% 2026 data
Asset Turnover 0.21 2026 data

EIKO Revenue, Net Profit & EBITDA — Year-on-Year Growth

EIKO YoY (Mar 2025 vs Mar 2026) — revenue +58.3%, net profit +100.0%, expenses +60.0%. For live price, earnings ratios and company overview, see EIKO Lifesciences stock price NSE.

Revenue Growth
+58.3%
Year-over-Year
Net Profit Growth
+100.0%
Year-over-Year
Expense Growth
+60.0%
Year-over-Year
Assets Growth
+34.8%
Year-over-Year
Equity Growth
+21.1%
Year-over-Year
Investing Cash Flow Growth
-1000.0%
Year-over-Year
Financing Cash Flow Growth
+600.0%
Year-over-Year

EIKO Income Statement — Revenue, EBITDA & Net Profit

EIKO Lifesciences revenue ₹19 Cr, EBITDA ₹2 Cr, net profit ₹2 Cr, EPS ₹0.93 (2026) — net profit margin 10.5%. Explore EIKO investment value to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars Mar 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Jun 2024 Dec 2024 Sept 2020 Mar 2020 Jun 2020 Sept 2019 Mar 2019 Jun 2019 Dec 2019 Sept 2018 Jun 2018 Dec 2018
Revenue 19 12 12 11 12 8 11 8 1 1 1 4 1 2 3 1 1 1
Expenses 16 10 10 9 10 8 10 7 1 2 0 6 2 3 5 1 1 1
EBITDA 2 2 2 2 2 1 1 1 0 -1 0 -2 0 0 -1 0 0 0
Operating Profit Margin % 12.00% 15.00% 12.00% 14.00% 16.00% 5.00% 4.00% 9.00% -6.00% -148.00% 25.00% -44.00% -26.00% -18.00% -42.00% -14.00% -9.00% -14.00%
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 2 2 2 2 2 0 1 1 0 -1 0 -2 -1 -1 -2 0 0 0
Tax 1 0 0 0 1 0 0 0 0 0 0 -1 0 0 0 0 0 0
Net Profit 2 1 1 1 1 0 0 0 0 -1 0 -1 0 0 -1 0 0 0
Earnings Per Share (₹) 0.93 0.78 0.80 0.66 0.88 0.22 0.29 0.32 -0.14 -1.08 0.17 -1.87 -0.58 -0.50 -1.55 -0.26 -0.25 -0.22

EIKO Balance Sheet — Assets, Liabilities & Shareholders' Equity

EIKO total assets ₹89 Cr, total equity ₹69 Cr, total liabilities ₹ Cr (2026) — ROE 2.9%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2020 2019 2018
ASSETS
Total Assets 89 66 12 9 11
Current Assets 47 33 5 4 6
Fixed Assets 22 23 2 2 2
Capital Work in Progress 0 0 0 0 0
Investments 4 7 0 2 3
Other Assets 0 36 10 6 6
LIABILITIES
Total Liabilities
Current Liabilities 4 3 2 0 1
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 69 57 1 5 6
Share Capital 14 14 4 4 4
Reserves & Surplus 54 43 -1 1 2

EIKO Cash Flow Statement — Operating, Investing & Financing

EIKO Lifesciences operating cash flow ₹3 Cr, investing ₹-11 Cr, financing ₹7 Cr, net cash flow ₹-2 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2020 March 2019 March 2018 March 2017
Operating Activities 3 0 0 0 0
Investing Activities -11 -1 0 0 0
Financing Activities 7 1 -1 0 0
Net Cash Flow -2 0 -1 0 0